High potency, fast acting, long lasting: Opticann’s CB4 Relief are amber-coloured oral soft gel capsules, providing medical patients with a fast-acting, high-potency CBD option combined with beta caryophyllene for synergy with 4x the CBD absorption of other typical soft gels. CB4 Relief soft gels also have 4x higher potency (based on peak absorption) and 3x faster onset (faster time to reach peak) versus most other oral CBD products. CB4 Relief soft gels from Opticann contain 25mg of CBD, and 13mg of beta-caryophyllene (BCP) per capsule. These two ingredients are reported to act on the cannabinoid receptors in the endocannabinoid system. CB4 Relief soft gels are THC free and are suitable for use for most patients any time of the day. These innovative CBD soft gel capsules are formulated with patented VESIsorb technology for increased and consistent bioavailability, offering maximum and safe CBD absorption when taken orally. VESIsorb is used to maintain the quality and stability of your medical cannabis.
Les gélules CB4 Relief-T d’Opticann contiennent chacune 25 mg de CBD, 13 mg de bêta-caryophyllène (BCP) et 0,75 mg de THC. Ces trois ingrédients agissent sur les récepteurs cannabinoïdes dans le système endocannabinoïde.
VESIsorbMD est une collection brevetée d’ingrédients naturels hydrosolubles utilisés par l’industrie pharmaceutique qui permettent de maintenir la qualité et la stabilité du produit.
L’absorption élevée des gélules CB4 Relief permet aux patients de prendre une seule dose une à deux fois par jour, le matin ou le soir, avec ou sans nourriture.
[]
Praesent feugiat tempor pulvinar. Maecenas ultrices mi augue, vitae volutpat libero tincidunt in. Morbi eu enim vehicula lectus efficitur vehicula et sed turpis. Maecenas tortor mauris, porta vitae eros mattis, semper vulputate purus. Quisque hendrerit ligula sed laoreet gravida. Mauris vel molestie dui.
Cannabis coverage for Veterans
Abba Vets
About Abba Medix
Blog
Healthcare Professionals
FAQ
Programs
Get prescribed
Register with Abba Medix
Contact us
Join our newsletter
